US China Innovation and Investment Summit Panel on Biopharmaceuticals to Feature Pulmotect CEO
Houston, TX, May 10, 2017 --(PR.com
)-- Pulmotect, Inc., clinical stage biotechnology company developing and commercializing an inhalant designed to prevent respiratory infections, announced today that Nestor Molfino, M.D., CEO, will participate in a panel discussion entitled “Innovation in Biopharmaceuticals” at the US China Innovation and Investment Summit, being held at the Omni Houston Hotel in Houston, Texas on May 16, 2017.
The 40-minute panel discussion will take place at 1 p.m. in Colonnade Salon A. Industry experts joining Molfino in the discussion on therapeutics are Mike Moradi, CEO and co-founder of Sensulin and Jon Northrup, CEO and co-founder of Beta Cat Pharmaceuticals.
Molfino, a respiratory medicine specialist, will provide his perspective on balancing the costs of developing and delivering innovative technologies, drug safety and regulatory issues, important learning to date and the future outlook of therapeutics in modern healthcare.
Molfino previously served as an independent consultant to biopharmaceutical companies, clinical research organizations (CROs), investors and patient organizations in the planning, designing and execution of drug development and commercial strategies. He was also the Chief Medical Officer at South San Francisco-based KaloBios Pharmaceuticals, Inc.
In addition to the panel discussion, Molfino will represent Pulmotect in the InnoSTARS preliminary stage pitch competition on Monday, May 15 for a chance to earn an expense-paid trip to China to showcase the company’s technology to potential partners and investors during a three-city tour.
The US China Innovation and Investment Summit will focus on five areas of industry including healthcare and biotechnology, agriculture and food safety, renewable energy, advanced manufacturing and information and communication technology. In addition to panel discussions, the summit will feature B2B Matchmaking sessions, an exhibition of technology companies and VIP meetings.
To learn more about the 2017 conference, visit http://uschinainnovation.org.
About Pulmotect, Inc.
Founded in 2007, Pulmotect’s technology is licensed from The Texas A&M University System and The University of Texas MD Anderson Cancer Center. Pulmotect partnered in 2008 with Fannin Innovation Studio, a Houston-based early-stage life science management and investment company, to assist in the drug’s commercial development. Pulmotect is the recipient of multiple early stage investments and grants, as well as recognition and awards from the biotechnology community, and the Company was awarded $7.1 million from the Cancer Prevention Institute of Texas (CPRIT). For more information, visit www.pulmotect.com.